What You Ought to Know:
– Eyenuk, Inc., a world synthetic intelligence (AI) digital well being firm and the chief in real-world functions for AI Eye Screening™ and AI Predictive Biomarkers™, as we speak introduced it has secured $26 million in a Sequence A financing spherical, bringing the Firm’s whole funding to over $43 million.
– The capital elevate was led by AXA IM Alts and was joined by new and present traders together with T&W Medical A/S, A&C Foelsgaard Alternativer ApS, Kendall Capital Companions, and KOFA Healthcare.
Accelerating World Entry to AI-Powered Eye-Screening Expertise
Eyenuk, Inc. is a world synthetic intelligence (AI) digital well being firm and the chief in real-world AI Eye Screening™ for autonomous illness detection and AI Predictive Biomarkers™ for threat evaluation and illness surveillance. Eyenuk is on a mission to display screen each eye on this planet to make sure well timed prognosis of life- and vision-threatening illnesses, together with diabetic retinopathy, glaucoma, age-related macular degeneration, stroke threat, cardiovascular threat, and Alzheimer’s illness.
Eyenuk will use the capital to broaden its AI product platform with further illness indications and superior care coordination and to speed up the platform’s world commercialization and adoption.
“We’re thrilled that AXA IM Alts, T&W Medical A/S, A&C Foelsgaard Alternativer ApS, Kendall Capital Companions, and our different new and present traders have joined us in furthering our mission of utilizing AI to display screen each eye on this planet to assist remove preventable imaginative and prescient loss and transition the world to predictive and preventative healthcare,” mentioned Eyenuk CEO and Founder Kaushal Solanki, Ph.D. “Our Sequence A fundraise validates the robust market efficiency of the EyeArt® system and offers us with vital sources as we broaden our platform capabilities this 12 months to incorporate options for detecting further illnesses.”
Right this moment’s announcement follows the Sept. 29, 2022 publication of a significant peer-reviewed research in Ophthalmology Science, a publication of the American Academy of Ophthalmology. The research discovered that the EyeArt AI system is way extra delicate in figuring out referable diabetic retinopathy than dilated eye exams by ophthalmologists and retina specialists.
Eyenuk is main the way in which in harnessing the ability of AI to remove preventable blindness globally, by way of its versatile digital well being platform that allows automated AI prognosis and coordination of care. Eyenuk’s flagship EyeArt AI system has been extra broadly adopted worldwide than another autonomous AI expertise for ophthalmology. Since its FDA clearance in 2020, the EyeArt system has been utilized in over 200 places in 18 nations, together with 14 U.S. states, to display screen over 60,000 sufferers and counting. It’s the first and solely expertise to be cleared by the FDA for autonomous detection of each referable and vision-threatening diabetic retinopathy with none eye care specialist involvement.
The EyeArt system is reimbursed by Medicare within the US, and has regulatory approvals globally, together with CE Marking, Well being Canada license, and approvals in a number of markets in Latin America and the Center East.